Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $95.00 at Bank of America

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target decreased by Bank of America from $97.00 to $95.00 in a research note issued to investors on Thursday, Benzinga reports. Bank of America currently has a neutral rating on the stock. Several other analysts have also recently weighed in on AXSM. Truist Financial reiterated a […]

Leave a Reply

Your email address will not be published.

Previous post Applied Therapeutics (NASDAQ:APLT) Stock Rating Reaffirmed by Royal Bank of Canada
Next post Bitfarms (NASDAQ:BITF) Earns “Buy” Rating from HC Wainwright